A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence
Abstract
Our trauma/hemorrhagic shock (T/HS) injury model was highly effective at causing acute respiratory distress syndrome (ARDS) in all Control groups. However, TRB-N0224 treatment, although it lowered both plasma and bronchoalveolar lavage (BALF) IL-6 levels, resulted in no significant improvement in clinical outcome, in the form of improve lung function (i.e lung compliance or PaO2/FiO2 ratio) or histopathology. We postulate that there were two problems with the study: 1) the stress of the gavage was an additional trauma in an already severe T/HS model and 2) the T/HS model causes severe damage to the gut, which significantly reducedTRB-N0224 adsorption. To solve this problem we have requested a one-year no-cost extension to use an intravenous formulation of TRB-N0224 that, if our postulate is correct, will solve both of our problems. As a secondary solution to our problem if the IV formulation of TRBN0224is not effective in the T/HS model we will try in our rat cecal ligation and puncture(CLP) model. This will determine if TRB-N0224 is effective for trauma and/or sepsis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2017
- Accession Number
- AD1045338
Entities
People
- Gary F Nieman
Organizations
- State University of New York Upstate Medical University